High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
There is no prospective data on 8 weeks of direct-acting antivirals (DAA) therapy with glecaprevir/pibrentasvir (GLE/PIB) or ledipasvir/sofosbuvir (LDV/SOF) in hepatitis C virus (HCV)-infected patients with different types of malignancies. This study evaluated the efficacy and safety with 8 weeks of DAA therapy in cancer patients with chronic HCV infection. Patients treated with DAAs at our center during 2014-2021 were included in a prospective observational study. Efficacy (sustained virologic response at 12 weeks; SVR12) and safety [adverse events and clinically significant drug-drug interactions (DDIs)] were assessed. We included 47 patients. Most were men (29; 62%), white (33; 70%), non-cirrhotic (45; 96%), and with HCV genotype 1 (38; 85%). None of the patients had HCC. The SVR12 rate was 96% (45/47; 95% CI: 86-99%) for the entire study cohort, 100% [17/17; 95% CI: 82-100%] for the patients treated with GLE/PIB and 93% [28/30; 95% CI: 79-98%] for the patients treated with LDV/SOF. Fisher's exact test showed no significant difference in SVR12 rates between the regimens (P = 0.53). No patients had serious adverse events (grade 3-4) or treatment discontinuation. Among the 17 patients who received concomitant cancer therapy, no DDIs occurred. Eight weeks of DAA therapy is highly effective and safe in HCV-infected patients with different types of malignancies and may grant access to investigational cancer therapy, broadening treatment options.
Identifiants
pubmed: 36062500
doi: 10.1097/MEG.0000000000002437
pii: 00042737-202210000-00016
doi:
Substances chimiques
Antiviral Agents
0
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1098-1101Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org . [Accessed 25 February 2021].
Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68:663–671.
AASLD-IDSA. HCV Guidance: Recommendations for testing m, and treating hepatitis C. Accessed April 25, 2022. [Available from: https://www.hcvguidelines.org/treatment-naive/gt1a/no-cirrhosis .
Mavyret (glecaprevir/pibrentasvir) [package insert]. AbbVie Inc., 2021
Harvoni (ledipasvir/sofosbuvir) [package insert]. Gilead Sciences Inc., 2020
Torres HA, Pundhir P, Mallet V. Hepatitis C virus infection in patients with cancer: Impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology 2019; 157:909–916.
U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf .
Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, et al. Oncologic implications of chronic hepatitis C virus infection. J Oncol Pract 2019; 15:629–637.
Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, et al. Sofosbuvir-based therapy in Hepatitis C Virus-infected cancer patients: a prospective observational study. Am J Gastroenterol 2019; 114:250–257.
Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68:663–671.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019; 49:1052–1059.
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-coinfected individuals: results from the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis 2016; 63:1320–1324.
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis 2018; 67:1010–1017.